Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Oligonucleotides in Maixuekang Capsules
NCT06823895Phase 1Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Maixuekang in ischemic stroke and thrombosis (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Sequence and expression level of oligonucleotides in plasma at 40 hours. Started Sep 2024; status: recruiting.
02
Drugs
Maixuekang
03
Conditions
ischemic strokethrombosis
Beyond the preview
Go deeper on NCT06823895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823895.